Black Men Less Likely to Get Monkeypox Vaccine

Black Men Less Likely to Get Monkeypox Vaccine
Black Men Less Likely to Get Monkeypox Vaccine

[ad_1]

By Steven Reinberg and Robin Foster HealthDay Reporters
HealthDay Reporter

MONDAY, Aug. 29, 2022 (HealthDay News) — Although there’s now enough monkeypox vaccine to go around, the Americans who need it most still may not be getting it, a new report shows.

Only 10% of the Jynneos vaccine doses have been given to Black people, even though they make up a third of U.S. cases, new data from the U.S. Centers for Disease Control and Prevention shows.

The latest statistics were only able to be gathered from 17 states and two cities, but similar disparities have already been reported by a few states and cities. So far, the monkeypox outbreak has largely affected gay and bisexual men.

The United States has the most infections of any country — over 17,000. About 98% of U.S. cases are men and about 93% were men who reported recent sexual contact with other men. No one in the United States has died from the illness, but deaths have been reported in other countries.

There could be several explanations for the troubling trend, experts say. It could be how and where shots are offered and publicized. Also, some Black men don’t trust doctors and government public health efforts, or they may be less likely to identify themselves as at greater risk for getting the virus.

Vaccine reluctance was also seen in Black communities when COVID-19 vaccines were rolled out, Dr. Yvens Laborde, director of global health education at Ochsner Health in New Orleans, told the Associated Press. “If we’re not careful, the same thing will happen here” with monkeypox, he said.

Black men are making up more monkeypox cases, Caitlin Rivers, a Johns Hopkins University expert on government response to epidemics, told the AP. “This is a problem that is not resolving,” she said.

The Biden administration said Friday it has shipped enough monkeypox vaccine to give the first of two doses to those at the highest risk. That’s nearly 2 million gay or bisexual men. The CDC, however, can’t break that down by race, the AP noted.

Enough second doses are expected by the end of September. As a stopgap, health officials have already recommended cutting doses to stretch the supply of the vaccine. According to the Biden administration, only 14 jurisdictions of 67 have used enough vaccine to ask for more from the federal stockpile.

Black men need to have more access to the vaccine, some experts say.

CDC director Dr. Rochelle Walensky, speaking at a White House briefing on Friday, said her agency has taken steps to increase vaccine access in Black communities. Vaccines and educational materials will be available at Atlanta’s upcoming Black Pride events and New Orlean’s Southern Decadence, the AP reported.

“We’ve seen as we’re starting to roll these pilot projects out that they are working,” she said.

To date:

  • About 50% of those who have gotten the vaccine are white and about 25% were Hispanic.
  • About 10% were Black and 10% were Asian.
  • About 94% were men, and 6% were women.
  • Over half of recipients were between the ages of 25 and 39.

In related news, a CDC survey released Friday showed that about half of gay and bisexual men are cutting back on sexual activity to avoid infection with monkeypox.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on monkeypox.

SOURCE: Associated Press

[ad_2]

Source link

ADHD Drug Adderall in Short Supply

ADHD Drug Adderall in Short Supply
ADHD Drug Adderall in Short Supply

[ad_1]

By Steven Reinberg HealthDay Reporter
HealthDay Reporter

MONDAY, Aug. 29, 2022 (HealthDay News) — Labor shortages at Teva Pharmaceuticals have made Adderall, a widely used attention-deficit/hyperactivity disorder (ADHD) drug, hard to find in some drugstores.

But the U.S. Food and Drug Administration noted that there’s no overall shortage of ADHD medications.

Only Teva is reporting supply problems, FDA spokeswomen Cherie Duvall-Jones told NBC News.

“Teva Pharmaceuticals, the maker for Adderall tablets, is reporting expected delays for the next 2-3 months,” she said.

Teva attributes the delay to a labor shortage on its packaging line, which it said has been resolved. The company added that while some pharmacies may have back-orders, it should be temporary.

“We expect full recovery for all inventory and orders in the coming weeks, at which point we expect no disruption at the pharmacy level,” spokeswoman Kelley Dougherty said in a statement, NBC News reported.

Large pharmacy chains have not seen a widespread problem: CVS said its locations were “not experiencing supply issues for Adderall and are able to fill prescriptions as received in most cases,” while Walgreens said its “current supply is meeting our patient needs at this time,” NBC News reported.

But small pharmacies are experiencing shortages: A National Community Pharmacists Association survey conducted from July 25 through Aug. 5 found that of about 360 independent drugstores, 64% had difficulty getting Adderall.

Byron Olson owner of Roger’s Family Pharmacy in Yankton, S.D., told NBC News that some forms of the drug have been harder to get than others.

“It’s often that they’re not out entirely,” he said, explaining that patients who take 20 milligrams (mg) twice a day, for example, might have to use alternative dosages. In some cases, patients might have to switch to another medication, he noted.

“It can be frustrating for patients because they don’t know about the shortages,” Olson said.

At Killingworth Family Pharmacy in Killingworth, Conn., owner Keith Lyke told NBC News that he has been getting patients from other drugstores who have been unable to fill their Adderall prescriptions. But generic forms from other makers have been easy enough to get, he said.

“We tell them it’s a different company, so it may look different,” he explained.

Dr. David Goodman, an assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, advised patients who take Adderall to anticipate difficulty with their prescription refills and to work with their doctors and pharmacies to get alternatives.

“It’s unpredictable. We can be sailing along fine and then we run into a shortage,” he told NBC News.

In the worst-case scenario — a patient who can’t get any medication — usually the shortage doesn’t last long.

“Usually it’s a matter of a few days or within a week,” he said.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on ADHD.

[ad_2]

Source link

Is There a Best Time of Day to Take Your Blood Pressure Pill?

Is There a Best Time of Day to Take Your Blood Pressure Pill?
Is There a Best Time of Day to Take Your Blood Pressure Pill?

[ad_1]

By Steven Reinberg HealthDay Reporter
HealthDay Reporter

MONDAY, Aug. 29, 2022 (HealthDay News) — It doesn’t seem to matter what time of day or night you take your blood pressure medication, a new study finds.

The results of a randomized trial of more than 21,000 patients with high blood pressure who were followed for over five years show that protection against heart attack, stroke and vascular death is not affected if the drugs are taken in the morning or evening.

These findings contradict previous research that suggested a large benefit when the medications are taken at night.

For the study, men and women were randomly assigned to take their blood pressure drugs in the morning or evening. The researchers then looked for hospitalization for heart attack, stroke, or death from cardiovascular disease.

Over a median of five years, 3.4% of those who took their medication at night and 3.7% of those who took their medication in the morning were hospitalized for heart attack, stroke or died from cardiovascular disease.

The findings were presented Friday at the annual meeting of the European Society of Cardiology, in Barcelona. Research presented at medical meetings is considered preliminary until published in a peer-reviewed journal.

The study “was one of the largest cardiovascular studies ever conducted and provides a definitive answer on the question of whether blood pressure-lowering medications should be taken in the morning or evening,” said researcher Thomas MacDonald, a research professor at the University of Dundee in Scotland.

“The trial clearly found that heart attack, stroke and vascular death occurred to a similar degree, regardless of the time of administration,” MacDonald said in a meeting news release. “People with high blood pressure should take their regular antihypertensive medications at a time of day that is convenient for them and minimizes any undesirable effects.”

More information

For more on high blood pressure, see the American Heart Association.

SOURCE: European Society of Cardiology, news release, Aug. 26, 2022

[ad_2]

Source link

Mental Health on Campus: Situation Grim, but Not Hopeless

Mental Health on Campus: Situation Grim, but Not Hopeless
Mental Health on Campus: Situation Grim, but Not Hopeless

[ad_1]

mental health crisis

Mental health issues among college students have increased by nearly 50% since 2013, one large study shows, now affecting 3 of every 5 students. Other researchers have found that the pandemic definitely contributed to a heavier toll on college students’ mental health.

[ad_2]

Source link

Hypertension in Pregnancy Is Getting More Common for Gen Z Women

Hypertension in Pregnancy Is Getting More Common for Gen Z Women
Hypertension in Pregnancy Is Getting More Common for Gen Z Women

[ad_1]

By Steven Reinberg HealthDay Reporter
HealthDay Reporter

MONDAY, Aug. 29, 2022 (HealthDay News) — Gen Zers and millennials are about twice as likely to develop high blood pressure during pregnancy than women from the baby boom generation were, a new study finds. This includes conditions such as preeclampsia and gestational hypertension.

It’s usually believed that the odds of developing high blood pressure during pregnancy rise with the age of the mother, but after taking age into account, researchers discovered that women born in and after 1981 were still at greater risk.

“While there are many reasons for the generational changes observed, we hypothesize that this is, in large part, due to the observed generational decline in heart health,” said study co-author Dr. Sadiya Khan, an assistant professor at Northwestern University Feinberg School of Medicine in Chicago. “We are seeing more people in more recent generations entering pregnancy with risk factors such as obesity.”

She emphasized that the stakes are high.

“High blood pressure during pregnancy is a leading cause of death for both mom and baby,” Khan said in a school news release. “High blood pressure during pregnancy is associated with increased risk of heart failure and stroke in the mother and increased risk of the baby being born prematurely, being growth restricted or dying.”

The researchers drew numbers from the National Vital Statistics System Natality Database. The study, which included data from more than 38 million women, focused on first pregnancies that occurred between 1995 and 2019.

These numbers allowed them to match high blood pressure-related disorders during pregnancy with mothers’ birth year and race or ethnicity.

They found that the highest rates were among American Indian, Alaskan Native and Black women.

“This is the first multi-generational study that moves beyond the age of the mom or the calendar year of the delivery to understand patterns of hypertension in pregnancy,” Khan said.

“This is especially important when we look at the legacy of substantial racial and ethnic disparities in this high-risk condition that affects not only the mom but also the baby,” she said. “This sets up a vicious cycle of generational health decline by starting life with poorer heart health.”

Co-author Dr. Natalie Cameron, an instructor of medicine at Northwestern, said the findings call for a new approach to screening.

“The public health and clinical message from this work is the need to broaden our perspective on screening and expand our focus on prevention in all age groups before and during pregnancy, particularly among younger people who have traditionally not been considered at high risk,” Cameron said in the release.

Khan agreed. “Prevention and earlier identification can be lifesaving and improve the health of future generations beginning at birth,” she said.

The study was published online Aug. 24 in JAMA Open Network .

More information

The U.S. Centers for Disease Control and Prevention has more about high blood pressure during pregnancy.

SOURCE: Northwestern Medicine, news release, Aug. 24, 2022

[ad_2]

Source link

Why Do We Lie About Our Health?

Why Do We Lie About Our Health?
Why Do We Lie About Our Health?

[ad_1]

Aug. 29, 2022 — The nurse practitioner called me before my virtual consult with my doctor with a few quick questions. “Have you felt depressed lately?” Nope, I said confidently, even though I’d been white-knuckling this parenting-two-little-kids-during-a-pandemic thing. “Great! That’s what we like to hear!” she replied.

In that moment, I felt proud – She’s so pleased with me! But why was I so quick to tell such a bald-faced lie?

The issue of lying about our health runs deep. Truth be told – no pun intended! – medical and health lying take multiple forms and they have different motivations and consequences.

Harmless Fib or Serious Problem?

A lot of us hide things during medical appointments, says Angie Fagerlin, PhD, population health sciences professor at the University of Utah.

“From our research, we know people aren’t telling their doctors the truth,” she says. Fagerlin and colleagues have published two papers about the phenomenon, with one more forthcoming about our COVID fibs.

One study, co-authored by Fagerlin and published in JAMA Network Open in 2018, analyzed survey responses from over 4,500 U.S. adults and their honesty surrounding common questions on their health habits, medical treatments, and experiences with their provider.

Most commonly, people admitted to lying to their provider when they either disagreed with their treatment recommendation or even when they didn’t understand what the doctor was saying in the first place.

Other reasons? They weren’t taking prescription meds as directed, didn’t exercise, ate an unhealthy diet, or were popping someone else’s prescription.

So why weren’t people fully fessing up?

“The number one most common response from 82% of patients is that they didn’t want to be judged or lectured about their behavior,” Fagerlin says. What’s more, 76% said they didn’t want to know that what they were doing was harmful, while 61% said they were embarrassed. Some patients even said they also didn’t want to come across as difficult or take up more of the doctor’s time.

Another study from Fagerlin and colleagues, published in 2019, analyzed disclosure of extreme and sometimes life-threatening challenges, such as depression, suicidal tendencies, abuse, and sexual assault. One quarter didn’t tell their provider largely because of embarrassment, fear of being judged, not wanting to pursue help (e.g., see a therapist), trying to avoid it being included on their medical record, or assuming their provider couldn’t help.

But this is counterintuitive – and counterproductive: We actively seek medical help and then actively prevent our physicians from providing proper, comprehensive care because we’re concerned about how we’re perceived.

Fagerlin agrees it can be mind-boggling, but it’s common.

“People tend to respect their providers and want them to think well of them. They don’t want to do something to harm that relationship or perception,” she says.

Meanwhile, your doctor won’t know to change your meds if you’re having problems, won’t know to look for drug interactions if you’re taking someone else’s prescription, or won’t be able to refer you to a mental health professional if they don’t know you’re struggling, Fagerlin says.

It’s not like we don’t want to be truthful. Quite the opposite. Research shows that people are willing to be open and honest, particularly about their mental health, when they thought they were talking to an online bot run by a computer, according to past research in Computers in Human Behavior.

“People shared more about their symptoms with the computer when they thought that there was no human involved compared to when they thought they were speaking with a person over technology,” says Gale Lucas, PhD, a research assistant professor at the University of Southern California.

Again, fear of being stigmatized or having a doctor think negatively of you were what fed the fibs, Lucas says. A computer won’t judge you, and we find that more comforting than being face-to-face with someone who might.

There’s Lying … and Then There’s Lying

Sometimes falsehoods go over the edge. These are the reports we often hear about people making up cancer diagnoses, repeatedly checking into hospitals, or self-inducing medical problems. Factitious disorder (once called Munchausen syndrome) is a mental illness in which one “feigns, exaggerates, or self-induces a medical problem in order to get attention, care, or concern that they feel unable to get any other way,” says Marc Feldman, MD, clinical professor of psychiatry at the University of Alabama and author of Dying to Be Ill.

About 1% of patients admitted to general hospitals are faking their symptoms, making it uncommon but not rare, Feldman says. Still, most in this group are those with stable jobs and relationships with loved ones and lie in this way off and on “when they can’t cope with the stress in their life and they need sympathy,” he says.

Having a high-status health care professional hang onto your every word is satisfying and brings a hint of belonging. And generally speaking, doctors are not taught to question patients, he says. Sometimes this sympathy can be gotten from family, friends, or fellow members of the community, and that can be sufficiently satisfying so that they don’t have to seek out a doctor at all.

Fewer people with factitious disorder make up this web of lies chronically, but some do, and weaving medical lies becomes a way of life.

“There are varying motives, but in my experience, the search for nurturance is number one. Others feel as if they don’t have control over their own lives, and manipulating professionals allows them to feel in control,” Feldman says.

Still, for some, it’s an underlying personality disorder driving chronic deceit. But for others, it’s profit. Some people make big money from their health fabrications, and experience big consequences in the bargain.

A California woman recently received 5 years in prison for wire fraud when her fake cancer diagnosis led to more than $100,000 in ill-gotten crowdfunding donations.

And earlier this year a writer for the TV show Grey’s Anatomy lost her job and reputation when her entire medical history – from a rare form of bone cancer to having an abortion while undergoing chemotherapy – was exposed as false. She fabricated all of it to fuel her writing career on the show and in national magazines.

For those who need genuine mental health care, help for factitious disorder is layered and complex, and there is a lack of providers with this type of expertise, Feldman says. Reduction strategies (including distraction when one has the urge to go to the hospital, for example) is one way mental health experts treat this condition, and simply talking to a therapist can help patients come to terms with the fact that their condition is psychological and not physical.

How to Fess Up – Not Fib

Part of the solution is realizing that lying about your health, on some level, provides you with a psychological reward – whether you’re under-reporting your wine consumption for brownie points or awash in sympathy from suggesting to a co-worker you have cancer.

But is that reward worth the consequences?

It can be tough to be vulnerable when owning up to medical truth, especially in a clinical environment where the balance of power seems skewed away from you. But avoiding the tough talks, and – even if they are small – the seemingly harmless fibs, can impact your ability to be successfully treated for a condition or stand in the way of making changes to daily habits that can benefit your health in the long term.

Knowing that you’re apt to lie or not tell the entire truth is the first step.

“Our research suggests that it’s a fear of evaluation that’s driving the choice not to open up. Awareness of that can potentially give you the power to make the difficult decision to share with providers,” Lucas says.

Another possibility: Talk frankly to your doctor about the difficulties, for example, of leading a healthy lifestyle. Most doctors will acknowledge and sympathize with that – “Hey, I know it’s tough to exercise regularly; it’s hard for me, too.” – and it becomes easier for patients to be truthful about their own habits and struggles. When a healthy lifestyle is made the default, almost all of us fall short.

“Going against the default is difficult for humans to do and admit to,” Fagerlin says. But know that “people who go into the medical profession want to help you live your best, healthiest life. They can’t do that if they don’t know the whole story.”

[ad_2]

Source link

Nearly 30% of U.S. Cancer Deaths Linked to Smoking

Nearly 30% of U.S. Cancer Deaths Linked to Smoking
Nearly 30% of U.S. Cancer Deaths Linked to Smoking

[ad_1]

Aug. 29, 2022 – Nearly 123,000 cancer deaths – or almost 30% of all cancer deaths – in the United States in 2019 were linked to cigarette smoking, a new analysis suggests.

That corresponds to more than 2 million person-years of lost life and nearly $21 billion in annual lost earnings.

“During the past few decades, smoking has substantially declined in the U.S., followed by great declines in mortality from lung cancer and some other smoking-related cancers,” says lead author Farhad Islami, MD, senior scientific director of cancer disparity research at the American Cancer Society.

Despite this “remarkable progress, our results indicate that smoking is still associated with about 30% of all cancer deaths and substantial lost earnings in the U.S., and that more work should be done to further reduce smoking in the country,” he says.

The study was published online Aug. 10 in the International Journal of Cancer.

Islami and colleagues had found that lost earnings from cancer deaths in 2015 came to nearly $95 billion. Other research showed that a substantial portion of lost earnings from cancer deaths could be traced to cigarette smoking, but estimates were more than a decade old.

To provide more recent estimates and help guide tobacco control policies, Islami and colleagues estimated person-years of life lost (PYLL)and lost earnings from cigarette smoking-related cancer deaths in 2019.

Of the 418,563 cancer deaths in adults ages 25 to 79 years, an estimated 122,951 could be linked to cigarette smoking. That corresponds to 29.4% of all cancer deaths and roughly 2.2 million PYLL. Translated to lost earnings, the authors estimated $20.9 billion total, with average lost earnings of $170,000 per cancer death linked to smoking.

By cancer type, lung cancer accounted for about 62%, or $12.9 billion, of the total lost earnings linked to smoking, followed by esophageal cancer (7%, or $1.5 billion), colorectal cancer (6%, or $1.2 billion), and liver cancer (5%, or $1.1 billion).

Smoking-related death rates were highest in the 13 “tobacco nation” states with weaker tobacco control policies and a higher rate of cigarette smoking. These states are Alabama, Arkansas, Indiana, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Ohio, Oklahoma, South Carolina, Tennessee, and West Virginia.

The lost earnings rate in all 13 tobacco nation states combined was about 44% higher, compared with other states and the District of Columbia combined, and the annual PYLL rate was 47% higher in tobacco nation states.

The researchers estimated that if PYLL and lost earnings rates in all states matched those in Utah, which has the lowest rates, more than half of the total PYLL and lost earnings nationally would have been avoided. In other words, that would mean 1.27 million PYLL and $10.5 billion saved in 2019.

Ending the ‘Scourge of Tobacco’

To kick the smoking habit, health providers should “screen patients for tobacco use, document tobacco use status, advise people who smoke to quit, and assist in attempts to quit,” Islami says.

Getting more people to screen for lung cancer in the U.S. is also important, given that only 6.6% of eligible people in 2019 received screening.

In a statement, Lisa Lacasse, president of the American Cancer Society Cancer Action Network, said this report “further demonstrates just how critical reducing tobacco use is to ending suffering and death from cancer.”

To end the “scourge of tobacco,” local, state, and federal lawmakers need to pass proven tobacco control policies, she said.

These include regular and significant tobacco tax increases, thorough statewide smoke-free laws, and enough funding for state programs to prevent and stop smoking. It also means ensuring all Medicaid enrollees have access to all services that can help smokers quit as well as access to all FDA-approved medications that help users stop smoking.

“We have the tools to get this done, we just need lawmakers to act,” Lacasse said.

[ad_2]

Source link

Salmon Burgers | Mark’s Daily Apple

Salmon Burgers | Mark’s Daily Apple
Salmon Burgers | Mark’s Daily Apple

[ad_1]

Salmon burger on white plate

Salmon burgers are the perfect dinner time meal. Not only are they nutritious, but when made on the stovetop are a quick meal to enjoy with the entire family. Plus, salmon includes vitamin D3, B-vitamins, magnesium, iron, and selenium. You can’t beat that. Our recipe also calls for a low-carb bun, but you can always switch it out for lettuce or collard greens. Our patties are so delicious and packed with flavor that we wouldn’t blame you if you even omitted the wrapping all together to eat the burger and and slaw on their own!

How to make salmon burgers

For this recipe we’re using wild-caught salmon filets, which include healthy omega-3 fats and far fewer toxins than farmed salmon. In order to prep the salmon you’ll want to cut the skin of the salmon away from the flesh. Then finely mince the salmon filet with a knife or by pulsing the salmon in a food processor. If you are using the food processor, cut the filet into large chunks, then pulse until a mince forms. Be sure not to over-process! The salmon should look similar to the below photo.

Minced salmon on a cutting board

Next, place the salmon in a bowl along with the egg, almond flour, green onion, bell pepper, mayo, coconut aminos, black pepper, coriander, onion powder, paprika, cumin and salt. Mix to combine. Form the salmon mixture into 4 equal sized patties and place on a sheet pan.

Raw salmon burgers on baking sheet

 

How to cook salmon burgers

The great part about this recipe for salmon burgers is there are multiple cooking methods! If you’re running short on time and don’t have time for cooking with an oven, throw these patties on the stovetop for an efficient cooking method.

  • Cook the salmon burgers in the oven: Before you start cooking ensure your oven is preheated to 375 degrees Fahrenheit.  Once your patties are formed bake for 18-22 minutes, or until the patties are firm and the salmon is fully cooked, flipping once during cooking. Set aside to cool.
  • Cook the salmon burgers on the stovetop: You can also make the burgers in a skillet on the stovetop. Heat a tablespoon or so of avocado oil in a skillet over medium heat and add the burgers. Cook for about 4 minutes on each side, or until the burger is cooked through.

Cooked salmon burgers on a baking sheet

Salmon burger toppings

Our salmon burgers also come with a homemade slaw made with broccoli or cabbage slow then tossed with the chipotle lime mayo and squeeze of lemon. You can also add extra minced red bell pepper or green onion to this mixture if you’d like. As for additional toppings, feel free to mix and match based on your liking! We used sliced tomato and red onion this time around.

Salmon burger with bun and toppings

Print

clock clock iconcutlery cutlery iconflag flag iconfolder folder iconinstagram instagram iconpinterest pinterest iconfacebook facebook iconprint print iconsquares squares iconheart heart iconheart solid heart solid icon

Description

Salmon burgers are the perfect dinner time meal. Not only are they nutritious, but when made on the stovetop are a quick meal to enjoy with the entire family.


Salmon Patties:

1 lb. wild-caught salmon filets

1 egg

2/3 cup almond flour

1/3 cup chopped green onion

1/3 cup minced red bell pepper

2 Tbsp Primal Kitchen Chipotle Lime Mayo

2 tsp coconut aminos

½ Tbsp Primal Kitchen Avocado Oil

½ tsp black pepper

½ tsp coriander

½ tsp onion powder

½ tsp paprika

¼ tsp cumin

¼ tsp salt

Slaw:

6 ounces broccoli or cabbage slaw

1.5 Tbsp Primal Kitchen Chipotle Lime Mayo

Squeeze of lemon juice

Fixings:

Your favorite low carb bun (we used UnBun) or lettuce for a lettuce wrap

Sliced tomato

Sliced red onion

Primal Kitchen Chipotle Lime Mayo


  • Preheat your oven to 375 degrees Fahrenheit.
  • Cut the skin of the salmon away from the flesh and finely mince the salmon filet with a knife or by pulsing the salmon in a food processor. If you are using the food processor, cut the filet into large chunks, then pulse until a mince forms, but do not over-process.
  • Place the salmon in a bowl along with the egg, almond flour, green onion, bell pepper, mayo, coconut aminos, black pepper, coriander, onion powder, paprika, cumin and salt. Mix to combine.
  • Form the salmon mixture into 4 equal sized patties and place on a sheet pan.
  • Bake for 18-22 minutes, or until the patties are firm and the salmon is fully cooked, flipping once during cooking. Set aside to cool.
  • Toss the slaw with the chipotle lime mayo and squeeze of lemon. You can also add extra minced red bell pepper or green onion to this mixture if you’d like.
  • Assemble your burgers by stacking the salmon burger on a bun or lettuce wrap, along with sliced tomato, red onion, the slaw and more chipotle lime mayo.

Notes

Lettuce or collard greens would be excellent low carb options to wrap these burgers in, or omit the wrapping all together and just eat the burger and slaw on their own.

You can also make the burgers in a skillet on the stovetop. Heat a tablespoon or so of avocado oil in a skillet over medium heat and add the burgers. Cook for about 4 minutes on each side, or until the burger is cooked through.

  • Prep Time: 15 minutes
  • Cook Time: 20 minutes

Nutrition

  • Serving Size: 1 burger patty, 1/4 of slaw
  • Calories: 426.6
  • Sugar: 4.9g
  • Sodium: 389.1mg
  • Fat: 27.6g
  • Saturated Fat: 3.6g
  • Trans Fat: 0g
  • Carbohydrates: 11.9g
  • Fiber: 2.9g
  • Protein: 33g
  • Cholesterol: 0mg
  • Net Carbs: 8.96g

 

About the Author

If you’d like to add an avatar to all of your comments click here!

[ad_2]

Source link

A Risky Monkeypox Vaccine Is Looking Better All the Time

A Risky Monkeypox Vaccine Is Looking Better All the Time
A Risky Monkeypox Vaccine Is Looking Better All the Time

[ad_1]

The transition from Monkeypox Inoculation Plan A to Monkeypox Inoculation Plan B has been a smashing success—at least, if you ask federal officials. Just a few weeks ago, the U.S. had nowhere near enough of the Jynneos vaccine to doubly dose even a quarter of the Americans at highest risk of monkeypox, roughly 1.6 million men who have sex with men. Now that the administration has asked that every dose of Jynneos be split into five and delivered a different way, between the layers of the skin, the party line has changed. “Everyone that wants to get vaccinated within that group is going to have an opportunity to get vaccinated” by September’s end, Robert Fenton, the White House’s monkeypox czar, said on a podcast last week.

But this new strategy of intradermal dosing “is a gamble,” says Caitlin Rivers, an epidemiologist at Johns Hopkins, and its weaknesses are already beginning to show. It may be high time to start acting on a fallback plan for our fallback plan, should Plan B’s high-stakes wager not pay off.

The Plan Cs on the table aren’t very palatable—which is probably why they’re Plan Cs. One option, largely dismissed early on, could entail turning to ACAM2000, a hypereffective smallpox shot, with sometimes dangerous side effects, that the U.S. has stockpiled in spades. Already, three jurisdictions, including the state of California, have ordered more than 800 doses of ACAM from the government, according to Timothy Granholm, a spokesperson for HHS.

Simply anticipating the possibility of Plan B’s failure might count as atypical for modern American public health—getting ahead of the virus du jour, rather than taking a reactive stance, says Stella Safo, an HIV physician in New York. Too often in the past few years, the institutions of public health have observed rather than acted, allowing SARS-CoV-2, and now monkeypox, to run roughshod over the American populace. “It would be really nice to not be saying, ‘Let’s wait and see,’” Safo told me. ACAM2000 may not be the country’s best or safest option for curtailing monkeypox, but the risk of not considering it may soon outweigh the risks of the shot itself.


There’s a world in which the U.S. didn’t even need a Monkeypox Inoculation Plan B. Had U.S. leaders been willing to invest resources in heading off the pathogen, by offering aid to countries where the virus has been endemic for decades or by focusing earlier this year on tests, treatments, vaccines, and public communications, maybe America’s original immunization plan—using the full, subcutaneous Jynneos dose—would have been all the nation needed on the injection front.

That didn’t happen, and instead the country adopted intradermal delivery, without real clarity on how well such doses might guard against infection, transmission, or disease. The notion that intradermal shots will work as hoped rests on a “chain of assumptions,” says John Beigel, an immunologist at the National Institute of Allergy and Infectious Diseases, several of which may not hold during a large, fast-spreading outbreak that’s tightly linked to sex—a poorly studied form of monkeypox transmission. Jynneos’s original approval was based on an antibody analogue of protection, rather than efficacy against bona fide illness. And the FDA’s authorization of intradermal shots rests on a single study, which didn’t directly check the vaccine’s ability to stave off disease, either. The study also enrolled only healthy adults, most of them white—a poor reflection of the population now being hit. It’s a “big leap” to build a nationwide vaccine campaign on just those results, says Sri Edupuganti, a vaccinologist at Emory University and one of the study’s authors. (Beigel is now designing a clinical trial that will reevaluate the intradermal route among participants more relevant to the current outbreak. He and his team will also test one-tenth intradermal doses, which could further stretch supply.)

The intradermal plan has logistical challenges, too. Administering in-skin shots requires extra training and special needles, burdening already stressed staff, especially in low-resource regions. Several jurisdictions are struggling to extract more than three or four doses from some vials, rather than the government’s promised five—a shortchanging of those hoping to increase their stocks by a clean 400 percent. Plus, some bottle caps are breaking before all the doses are withdrawn. Intradermal vaccination can also come with grating side effects, including redness and swelling that can stick around for days, potentially deterring people from returning for the essential second shot.

Fenton, from the White House, noted in a press briefing last week that the switch to intradermal “increased our supplies significantly without compromising safety or effectiveness.” But that assertion seems “disingenuous at best,” says Gregg Gonsalves, an epidemiologist and AIDS activist at Yale’s School of Public Health. Even the CEO of Bavarian Nordic, the vaccine’s manufacturer, criticized the FDA’s pivot as too hasty. (The FDA attempted to counter the company’s criticisms.)

Meanwhile, demand may continue to grow, especially if the epidemic starts to concentrate less among men who have sex with men. “The longer the outbreak lasts, the longer you have for jumping to other populations,” Gonsalves told me. College campuses, reopening now, “seem like the most obvious next stop.” And “if this gets into other networks,” says Ina Park, a sexual-health expert at UC San Francisco, Plan B “just won’t be enough.”

Equity, too, is becoming an issue. “If we lived in a world where we had plenty of vaccine, you would go with subcutaneous,” Beigel told me. But in North Carolina, for instance, where 70 percent of monkeypox cases have been among Black men, some two-thirds of the subcutaneous shots administered before August 8 went to people who are white; similar skews have been noted in New York City. Now “Black and brown gay men are really angry,” says Kenyon Farrow, a writer and public-health activist based in Ohio. “They watched white gay men get full doses … and now they feel like they are getting less of a dose.” Farrow has pushed for everyone to get at least one subcutaneous shot—a strategy that advocates in New York City also back—but the Biden administration seems set on moving all jurisdictions onto the intradermal route.


Mapping out yet another vaccination strategy won’t address all of these problems. (And no matter what, the administration should keep ordering more Jynneos, stat.) But the forecast for fall is murky. And should the present situation worsen, a fresh tactic could give the U.S. a head start—something the country hasn’t had on the public-health playing field in a while.

Already, some experts are mulling the nuclear option: ACAM2000, the smallpox shot that the government has been hoarding to counter a potential bioterrorism attack. Doses of the vaccine are available by the many millions, and thought to be both effective and durable. It’s also, Edupuganti told me, “one of the vaccines with the highest amount of adverse reactions,” occasionally triggering side effects as serious as heart inflammation. The shot contains a replicating virus, and shouldn’t be taken by immunocompromised people, including many of those who are living with HIV. And just about everyone who gets the shot sprouts an oozy lesion at the injection site that can pass the vaccine virus to others. Against something like smallpox—a far more contagious virus that killed up to 30 percent of its victims—ACAM2000 would be “a no-brainer,” says Rafi Ahmed, a vaccinologist at Emory University. With monkeypox, though, Johns Hopkins’s Rivers told me, the risk-benefit calculation “is really hazy.”

It’s not time to trot out ACAM yet, Safo, the New York physician, told me. But maybe autumn will bring many more cases. Maybe monkeypox’s symptoms could grow more severe. Maybe the virus will start to surge in new populations. Maybe intradermal Jynneos will fall short in effectiveness or safety. In any case, containment with the current tools isn’t a guarantee. “If things do get out of control,” Ahmed told me, “you want to have some ACAM stocks ready to go.” No clear, perfect threshold can yet denote “out of control.” Still, a trend toward a worse outbreak would inch the country closer to tapping into its ACAM2000 supply, Park told me: “I don’t think we have another choice.” Which means that the FDA and CDC should probably start poring over the ACAM data now, Rivers said.

Resorting to ACAM2000 will also put the onus on officials to explain to the public what they’re getting into. If some are balking at intradermal shots, people further back in line could reasonably wonder why they’ve been stuck with a less-safe vaccine, Farrow pointed out. There could be a middle ground worth testing in a clinical trial: one shot of Jynneos, via either administration route, followed by a dose of ACAM2000, says Stephen Goldstein, a virologist at the University of Utah. One 2019 study hints that this shot, chaser approach could shrink infectious lesions, as well as cut down on ACAM2000’s side effects, while still offering an immunological boost—though that trial used two subcutaneous Jynneos doses first. In any case, the government would do well to pursue more options, even enroll people in trials comparing the different vaccines, Gonsalves told me. And transparency is tantamount. “Back in the days of AIDS,” he said, “many of us were saying, as new drugs were coming online, we wanted access and answers” about the options at hand. Right now, the nation’s short on both.

That “we’re even having to ask these questions about ACAM,” Farrow told me, is a sobering reminder that “we didn’t get our shit together” early on. Instead, the U.S. has backed itself into having to reckon with its appetite for risk. Being too cautious with vaccines could allow the outbreak to further balloon; being too reckless with shots could compromise public trust. The administration firmly contends that Jynneos remains “the best available option,” according to Granholm, the HHS spokesman. (That said, ACAM2000 “is available upon request,” he told me.)

Such a position may feel like the safe one—it potentially sidesteps the gnarliness of ACAM. But perhaps it’s actually dicier, because it’s not properly preparative. “We can’t just say intradermal is going to solve all of our problems,” Park told me. Although the hope is that the country’s ACAM supply can stay stashed away, we need to be ready to use it, and quickly, should the need arise. If the country once again waits until “we’re in a pinch” to act, Rivers told me, “it’s going to be too late.”

[ad_2]

Source link